Handelsavisen
prelaunch
Companies ›Healthcare ›2135.HK
21
2135.HK — HKEX Healthcare Facilities & Services

2135.Hk

HK$0,12
Open in Charts → Attach watcher ⌖
— —
HKD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
1,8 %
ROE
1,7 %
Net margin
1,0 %
Debt / equity
0,55
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

The company operates in the healthcare sector, primarily engaged in pharmaceuticals and healthcare facilities and services, generating revenue through the production and sale of pharmaceutical products.

Business. The company operates in the healthcare sector, primarily engaged in pharmaceuticals and healthcare facilities and services, generating revenue through the production and sale of pharmaceutical products.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
ActivityPharmaceuticals
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership
—
not yet wired
Profitability→
1,7 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 2135.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 2135.HK. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    The company operates in the healthcare sector, primarily engaged in pharmaceuticals and healthcare facilities and services, generating revenue through the production and sale of pharmaceutical products.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryHealthcare Facilities & Services
    ActivityPharmaceuticals
    AI synthesis
    GENERATED

    The company maintains a debt-to-equity ratio of 0.55, indicating a moderate level of leverage, and a current ratio of 0.77, suggesting potential liquidity constraints. Free cash flow stands at 8.22 million CNY, while operating cash flow is 36.71 million CNY, reflecting a positive cash generation capability. However, the company's net cash position is negative after subtracting total debt, signaling a liquidity risk.

    Profitability metrics show a return on equity of 1.74% and a return on assets of 0.79%, both below the industry median for healthcare facilities and services, indicating suboptimal capital efficiency. The operating margin is 1.78%, and the net profit margin is 0.99%, which are also below the industry average, suggesting challenges in maintaining profitability.

    The company's revenue is concentrated in a single segment, with no disclosed geographic diversification, making it vulnerable to regional economic or regulatory shifts. There is no information on specific geographic revenue distribution, but the lack of segmental or geographic diversification increases exposure to localized risks.

    Looking ahead, the company is expected to maintain a stable revenue trajectory, with no significant growth or decline projected in the next fiscal year. Historical revenue data shows a consistent but modest performance, with no clear upward or downward trend. The company's capital expenditure is negative at -12.10 million CNY, indicating a reduction in investment in physical assets.

    The company faces a medium liquidity risk due to its current ratio of 0.77 and a negative net cash position after debt. Dilution risk is assessed as low, with no significant dilution potential in the near term. However, the company's financial structure and cash flow dynamics suggest a need for careful monitoring of liquidity and capital structure.

    There are no recent events or filings disclosed in the provided data that would significantly impact the company's operations or financial position. The absence of recent events does not imply stability, but rather a lack of disclosed material changes.

    Key takeaways
    • The company has a moderate debt-to-equity ratio but faces liquidity constraints as indicated by a current ratio below 1.
    • Profitability metrics are below industry medians, suggesting inefficiencies in capital and asset utilization.
    • Revenue is concentrated in a single segment with no geographic diversification, increasing exposure to localized risks.
    • The company is expected to maintain a stable revenue trajectory with no significant growth or decline projected.
    • Liquidity risk is medium, and dilution risk is low, but the company's financial structure requires close monitoring.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    HK$0,12
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    HK$107.8M
    Net cashⓘ
    -HK$59.2M
    Current ratioⓘ
    0.8
    Debt / equityⓘ
    0.6
    ROAⓘ
    0.8%
    ROEⓘ
    1.7%
    Cash conversionⓘ
    1960.0%
    CapEx / revenueⓘ
    -6.4%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin1,8 %Below median
    Net Margin1,0 %Below median
    ROE1,7 %Below median
    Capex / Rev-6,4 %Above median
    D/E0,55Below median
    Cash Conv19,60Best in class

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • 2135.HK Market data — financials · 2026-05-26

    Ownership & reference

    Leadership

    • Haishu FuExecutive Chairman of the Board
    • Jianliang SongChief Executive Officer, Executive Director

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    2135.HKCanonical
    HKEX · HKD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage